Bio-Reference Laboratories also receives warrants for 675,000 shares
By Devika Patel
Knoxville, Tenn., May 1 - IncellDx, Inc. raised $6 million from a private placement of promissory notes and preferred stock with Bio-Reference Laboratories, Inc. on April 27, according to an 8-K filed Tuesday with the Securities and Exchange Commission.
The $2 million promissory note is payable on an as-needed basis.
As a part of the deal, Bio-Reference also bought 3,636,364 series A-1 preferred shares for $4 million.
Bio-Reference also received warrants for 675,000 shares. The warrants are exercisable at $1.65.
IncellDx is a private molecular diagnostics company based in Menlo Park, Calif. It is in the start-up phase and is currently unprofitable, with assets of unknown market value.
| Issuer: | IncellDx, Inc.
|
| Issue: | Promissory notes, series A-1 preferred shares
|
| Amount: | $6 million
|
| Warrants: | For 675,000 shares
|
| Warrant strike price: | $1.65
|
| Investor: | Bio-Reference Laboratories, Inc.
|
| Settlement date: | April 27
|
|
|
| Notes
|
| Amount: | $2 million
|
|
|
| Preferreds
|
| Amount: | $4 million
|
| Shares: | 3,636,364
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
